These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2274011)

  • 21. [Medical treatment of acromegaly with dopaminergic agents].
    Liuzzi A; Dallabonzana D; Oppizzi G; Cozzi R; Chiodini PG
    Minerva Endocrinol; 1990; 15(1):23-7. PubMed ID: 1980333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resolution of acromegalic cardiomyopathy in mild acromegalic physical abnormality after short-term octreotide therapy.
    Hwang MW; Shimatsu A; Sasaki Y; Ayukawa H; Inenaga K; Takeoka R; Iwase T; Kawai C
    Heart Vessels; 2007 May; 22(3):202-7. PubMed ID: 17533526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical application of somatostatin-analogue].
    Tanaka K; Itoh S; Shimizu N
    Nihon Rinsho; 1990 May; 48(5):1084-8. PubMed ID: 2165538
    [No Abstract]   [Full Text] [Related]  

  • 24. Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.
    Shi YF; Zhu XF; Harris AG; Zhang JX; Dai Q
    J Clin Endocrinol Metab; 1993 Jan; 76(1):32-7. PubMed ID: 8421099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does preoperative somatostatin analog treatment improve surgical cure rates in acromegaly? A new look at an old question.
    Beckers A
    J Clin Endocrinol Metab; 2008 Aug; 93(8):2975-7. PubMed ID: 18685119
    [No Abstract]   [Full Text] [Related]  

  • 26. Combined octreotide and insulin therapy in acromegaly.
    Weber SL; Gkonos PJ; Skyler JS
    Endocr Pract; 1997; 3(1):19-21. PubMed ID: 15251489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of octreotide on glucose tolerance in acromegaly.
    Koop BL; Harris AG; Ezzat S
    Eur J Endocrinol; 1994 Jun; 130(6):581-6. PubMed ID: 8205258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consensus statement: benefits versus risks of medical therapy for acromegaly.
    Acromegaly Therapy Consensus Development Panel
    Am J Med; 1994 Nov; 97(5):468-73. PubMed ID: 7977436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analgesic effect of the somatostatin analogue octreotide in two acromegalic patients: a double-blind study with long-term follow-up.
    Schmidt K; Althoff PH; Harris AG; Prestele H; Schumm-Draeger PM; Usadel KH
    Pain; 1993 May; 53(2):223-227. PubMed ID: 8336992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging drugs for acromegaly.
    Störmann S; Schopohl J
    Expert Opin Emerg Drugs; 2014 Mar; 19(1):79-97. PubMed ID: 24400774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic aspects of acromegaly and its treatment.
    Quabbe HJ; Plöckinger U
    Metabolism; 1996 Aug; 45(8 Suppl 1):61-2. PubMed ID: 8769384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of antibody formation during long-term subcutaneous treatment with the somatostatin analogue octreotide in acromegaly.
    van Liessum PA; Swinkels LM; Pieters GF; Ross AA; Smals AG; Benraad TJ; Kloppenborg PW
    Acta Endocrinol (Copenh); 1990 Mar; 122(3):309-12. PubMed ID: 2183534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The pharmacological treatment of digestive endocrine tumors with the somatostatin analog SMS 201-995].
    Varas Lorenzo MJ
    Rev Clin Esp; 1991 Jan; 188(1):4-6. PubMed ID: 2063026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Desensitization treatment for hypersensitivity reaction to octreotide in an acromegalic patient.
    Dadzie DD; Lee EJ; Monteleone CA; Schneider SH
    Pituitary; 2012 Dec; 15 Suppl 1():S68-71. PubMed ID: 22618955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.
    Battershill PE; Clissold SP
    Drugs; 1989 Nov; 38(5):658-702. PubMed ID: 2689136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Living with acromegaly.
    Ezzat S
    Endocrinol Metab Clin North Am; 1992 Sep; 21(3):753-60. PubMed ID: 1521520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Somatostatin analog withdrawal in patients with acromegaly: an elusive goal?
    Mercado M
    Endocrine; 2014 Aug; 46(3):368-9. PubMed ID: 24736999
    [No Abstract]   [Full Text] [Related]  

  • 38. Octreotide: a synthetic analog of somatostatin.
    Rosenberg JM
    Drug Intell Clin Pharm; 1988 Oct; 22(10):748-54. PubMed ID: 3068036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is presurgical treatment with somatostatin analogs necessary in acromegalic patients?
    Losa M; Mortini P; Giovanelli M
    J Endocrinol Invest; 1999 Dec; 22(11):871-3. PubMed ID: 10710277
    [No Abstract]   [Full Text] [Related]  

  • 40. Increased deoxycholic acid absorption and gall stones in acromegalic patients treated with octreotide: more evidence for a connection between slow transit constipation and gall stones.
    Hofmann AF
    Gut; 2005 May; 54(5):575-8. PubMed ID: 15831896
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.